Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158214 | 0.89 | ABL1 (0.59) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL29975337 | 0.85 | ABL1 (0.53) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL29975654 | 0.82 | ABL1 (0.36) | ABL1RIN1P2RY6SMN1; SMN2 | |
| SCHEMBL15090413 | 0.80 | ABL1 (0.70) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL14980414 | 0.80 | ABL1 (0.70) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL29975987 | 0.80 | NT5M (0.38) | — | |
| SCHEMBL23565661 | 0.79 | ABL1 (0.61) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL27158019 | 0.79 | ABL1 (0.47) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL30937947 | 0.77 | ABL1 (0.53) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL21361135 | 0.77 | ABL1 (0.53) | ABL1RIN1POLBP2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2024-08-01 | — | — | US | claimed |
| EP-4332111-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2024-03-06 | — | — | EP | claimed |
| WO-2022230954-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2022-11-03 | — | — | WO | claimed |
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2024-08-01 | — | — | US | disclosed |
| EP-4332111-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022230954-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, CYC1, MRM1 | ABL1 3283/4885RIN1 3783/4885POLB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.